B
Boundless Bio, Inc. (BOLD)
NMS – Real Time Price. Currency in USD
1.55
+0.05 (3.31%)
Market open: May 13, 2026, 1:38 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
1.55
+0.05 (3.31%)
Market open: May 13, 2026, 1:38 PM EDT
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Christian Hassig Ph.D. | Chief Scientific Officer |
| Dr. James L. Freddo M.D. | Interim Chief Medical Officer |
| Dr. Robert C. Doebele M.D., Ph.D. | Chief Medical Officer |
| Mr. David Hinkle | Senior VP of Finance, Controller & Corporate Treasurer |
| Mr. Zachary D. Hornby | CEO, President & Director |
| Ms. Amy Berkley Ph.D. | Senior Vice President of Program Team |
| Ms. Jessica Oien J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Meredith Wesley | Chief Human Resources Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-08 | 10-Q | bold-20260331.htm |
| 2026-04-28 | DEFA14A | bold_defa14a_2026_.htm |
| 2026-04-13 | 8-K | bold-20260413.htm |
| 2026-03-09 | 8-K | bold-20260303.htm |
| 2025-11-05 | 8-K | bold-20251105.htm |
| 2025-11-05 | 10-Q | bold-20250930.htm |
| 2025-08-05 | 8-K | bold-20250805.htm |
| 2025-08-05 | 10-Q | bold-20250630.htm |
| 2025-06-23 | 8-K | bold-20250623.htm |
| 2025-05-23 | 8-K | bold-20250523.htm |